Kymera Therapeutics Overview
Kymera Therapeutics Target Price
Analysts' 12-month price predictions for KYMR.
Get informed when a big investor buys or sells
+ FollowShare Price
$113.51
Average Target Price
$121.20
6.8% upside
6.8% upside5 analysts in the last 4 months
High: $155 | Low: $97
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-26 | Canaccord GenuityEdward Nash | $129 | 13.6% upside |  |
| 2026-06-26 | B.Riley FinancialKalpit Patel | $155 | 36.6% upside | |
| 2026-06-08 | Loop Capital MarketsLeah Rush Cann | $97 |  14.5% downside | |
| 2026-05-06 | Canaccord GenuityEdward Nash | $106 | 6.6% downside | |
| 2026-04-30 | Morgan StanleyJudah Frommer | $119 | 4.8% upside | |
| 2026-02-26 | Morgan StanleyJudah Frommer | $123 | 8.4% upside | |
| 2026-02-26 | RBC CapitalBrian Abrahams | $108 | 4.9% downside | |
| 2026-01-27 | BarclaysEliana Merle | $133 | 17.2% upside | |
| 2025-12-16 | RBC Capital | $103 | 9.3% downside | |
| 2025-12-11 | StephensSudan Loganathan | $110 | 3.1% downside | |
| 2025-12-11 | Mizuho Securities | $120 | 5.7% upside | |
| 2025-12-09 | Jefferies | $122 | 7.5% upside | |
| 2025-12-09 | Truist FinancialSrikripa Devarakonda | $116 | 2.2% upside | |
| 2025-12-09 | H.C. WainwrightAndrew Fein | $134 | 18.1% upside | |
| 2025-12-09 | Oppenheimer | $120 | 5.7% upside | |
| 2025-12-09 | Morgan Stanley | $127 | 11.9% upside | |
| 2025-12-09 | Piper Sandler | $125 | 10.1% upside | |
| 2025-12-09 | Wells FargoDerek Archila | $116 | 2.2% upside | |
| 2025-12-09 | Barclays | $119 | 4.8% upside | |
| 2025-12-08 | Leerink Partners | $118 | 4% upside | |
| 2025-12-08 | BTIGJeet Mukherjee | $138 | 21.6% upside | |
| 2025-12-08 | Stifel NicolausAlex Thompson | $114 | 0.4% upside | |
| 2025-11-26 | Truist Financial | $80 | 29.5% downside | |
| 2025-11-26 | UBS | $90 | 20.7% downside | |
| 2025-11-05 | H.C. Wainwright | $84 | 26% downside | |
| 2025-11-05 | Barclays | $70 | 38.3% downside | |
| 2025-11-04 | Morgan Stanley | $73 | 35.7% downside | |
| 2025-11-04 | Jefferies | $73 | 35.7% downside | |
| 2025-11-04 | OppenheimerJeff Jones | $67 | 41% downside | |
| 2025-11-03 | GuggenheimBrad Canino | $90 | 20.7% downside | |
| 2025-10-22 | BTIGJeet Mukherjee | $75 | 33.9% downside | |
| 2025-10-01 | Oppenheimer | $63 | 44.5% downside | |
| 2025-09-30 | Truist Financial | $68 | 40.1% downside | |
| 2025-09-18 | H.C. Wainwright | $70 | 38.3% downside | |
| 2025-09-16 | Barclays | $60 | 47.1% downside | |
| 2025-09-16 | RBC CapitalBrian Abrahams | $70 | 38.3% downside | |
| 2025-06-27 | OppenheimerJeff Jones | $53 | 53.3% downside | |
| 2025-06-26 | BTIGJeet Mukherjee | $59 | 48% downside | |
| 2025-06-25 | JefferiesKelly Shi | $64 | 43.6% downside | |
| 2025-06-03 | GuggenheimMichael Schmidt | $60 | 47.1% downside | |
| 2025-02-28 | H.C. Wainwright | $54 | 52.4% downside | |
| 2024-12-05 | BMO CapitalEtzer Darout | $55 | 51.5% downside | |
| 2024-12-02 | Wells FargoDerek Archila | $57 | 49.8% downside | |
| 2024-09-27 | OppenheimerJeff Jones | $56 | 50.7% downside | |
| 2024-08-26 | Wolfe ResearchAndy Chen | $65 | 42.7% downside | |
| 2024-08-08 | H.C. WainwrightAndrew Fein | $60 | 47.1% downside | |
| 2024-06-17 | H.C. WainwrightAndrew Fein | $46 | 59.5% downside | |
| 2024-05-23 | Piper SandlerEdward Tenthoff | $56 | 50.7% downside | |
| 2024-05-03 | OppenheimerJeff Jones | $52 | 54.2% downside | |
| 2023-01-03 | Wells Fargo | $42 | 63% downside | |